SLCO2B1 and hepatocellular carcinoma: In addition, as expected, the treatment with CHIR99021 which functions as an activator of β-catenin signaling pathway clearly decreased the expression of HNF4α and OATP2B1, and overexpression of HNF4α restored the protein level of OATP2B1 in HCC cells (Figure 6D).